Basilea reported FY2018 revenue growth of 31% to CHF133m, driven by antifungal Cresemba. We expect limited revenue growth in 2019E, but note that there will be a shift towards cash-generating revenues, since deferred revenue of CHF23.9m related to Toctino will be replaced by contributions from Cresemba and antibiotic Zevtera (we forecast +30% YoY), translating to a reduction in net cash burn. With the commercialisation of Cresemba and Zevtera handed over to partners, Basilea is fully focused on ....
28 Feb 2019
Cresemba on track, pipeline expanding
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cresemba on track, pipeline expanding
Basilea Pharmaceutica AG (0QNA:LON) | 0 0 0.0% | Mkt Cap: 605.3m
- Published:
28 Feb 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
15
Basilea reported FY2018 revenue growth of 31% to CHF133m, driven by antifungal Cresemba. We expect limited revenue growth in 2019E, but note that there will be a shift towards cash-generating revenues, since deferred revenue of CHF23.9m related to Toctino will be replaced by contributions from Cresemba and antibiotic Zevtera (we forecast +30% YoY), translating to a reduction in net cash burn. With the commercialisation of Cresemba and Zevtera handed over to partners, Basilea is fully focused on ....